Toxoplasmosis Infection Treatment Market

Toxoplasmosis Infection Treatment Market Overview

Toxoplasmosis caused by a single celled parasite called “Toxoplasma gondii”, which results in an infection usually occurs by raw or undercooked contaminated meat particularly lamb or pork, drinking contaminated water and milk from an infected goat, exposure from cat feces, mother to child transmission during pregnancy and organs transplantation in rare cases.

Toxoplasmosis Infections causes flu like symptoms including muscle ache, body ache, fever, headache, sore throat, fatigue, swollen lymph nodes and swollen glands etc. People with weakened immune system develop more severe signs of infection and inflammation including brain inflammation, lung infection, poor coordination and blurred vision and eye infection.

Some factors including HIV/AIDS positive individuals, or undergoing chemotherapy patients and pregnant ladies having a risk of serious health problems. Medication for HIV/AIDS positive individuals, consist pyrimethamine and sulfadiazine, with folinic acid (leucovorin) given on the treatment choice. Pyrimethamine with clindamycin (Cleocin) used as an alternative source.

Sulfadiazine, which is an antibiotic used in combination with pyrimethamine to treat toxoplasmosis. During pregnancy, if the infection occurred after the 16th week, spiramycin (antibiotic) recommended in the first three months or in the second early trimester to treat the infection that reduces the risk of neurological problems in the baby. The combination of sulfadoxine with pyrimethamine is also used to prevent certain types of malaria. The treatment of toxoplasmosis includes a blood test to check the presence of antibodies of the related parasite.

Doctors typically prescribe medication consist antibiotic to treat the infection. The medication is depending on eye lesion size, type of the lesion (acute active, versus chronic not progressing) and the location of the infection.

Toxoplasmosis Infection Treatment Market: Drivers and Restrains

The toxoplasmosis infection treatment market is expected to be driven by the rising health awareness, high incidences of foodborne illness. With the increasing incidence of toxoplasmosis, and high investment in toxoplasmosis research, the market is expected to grow during the forecast period. However, certain side effects of high dosage drugs that includes blood disorders, allergic reactions, tongue changes and anorexia etc are posing a restrain to toxoplasmosis infection treatment market.

Toxoplasmosis Infection Treatment Market: Overview

The toxoplasmosis infection treatment market is expected to growth at a healthy growth rate during the forecast period. This is due to high incidence of Toxoplasmosis, an infectious disease caused by a protozoan. Government initiatives to prevent risk of toxoplasmosis and other infection from food is expected to drive the market during the forecast years.

Toxoplasmosis Infection Treatment Market: Regional overview

Region wise, the global toxoplasmosis infection treatment market is classified into seven regions namely North America, Latin America, Eastern Europe, Western Europe, Japan, Asia-Pacific excluding Japan, Middle East and Africa. North America is expected to hold the highest market share with strong growth of pyrimethamine treatment market.

Better government initiatives to educate people on the prevention of toxoplasmosis would reduce risk in the environment and open more business opportunities for research and development. The second largest market hold by Europe market followed by Asia pacific excluding Japan.

Toxoplasmosis Infection Treatment Market: Key Players

Some of the major players in toxoplasmosis infection treatment market include Impax Laboratories Inc., Turing Pharmaceuticals, Lupin Limited, Amneal Pharmaceuticals, Turing pharmaceuticals LLC, Pharmaceuticals LLC, Novartis International AG, F. Hoffmann-La Roche AG., Gilead Sciences, Greenstone LLC and others.

The report covers exhaustive analysis on

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Value Chain

Regional analysis includes

• North America (U.S., Canada)
• Latin America (Mexico, Brazil)
• Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX)
• Eastern Europe (Russia, Poland, Rest Of Eastern Europe)
• Asia Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
• Japan
• Middle East and Africa (GCC, S. Africa, N. Africa, Rest Of MEA)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Toxoplasmosis Infection Treatment Market: Segmentation

The global toxoplasmosis infection treatment market is classified on the drug type and the distribution channel.

Global Toxoplasmosis Infection Treatment Market, by drugs type-

• Pyrimethamine Combination
• Sulfadiazine Combination
• Leucovorin Combination (Folinic acid)
• Spiramycin Combination
• Clindamycin Combination
• Atovaquone Combination

Global Toxoplasmosis Infection Treatment Market, by distribution channel-

• Hospital Pharmacies
• Drug stores
• Retail pharmacy
• E-commerce
• Others